Skip to main content
. 2021 Dec 8;41(12):BSR20192007. doi: 10.1042/BSR20192007

Figure 4. MiR-27a-3p added the cisplatin sensitivity potentially by inhibiting PI3K/Akt pathway.

Figure 4

(A,B) MiR-27a group inhibited PI3K/p-Akt signaling and elevated C-caspase-3 in HepG2. MiR-inhibitor-27a group exhibited the opposite trend in PLC cells. And DDP group showed suppression of PI3K/p-Akt pathway and up-regulation of C-caspase-3. MiR-27a+DDP group showed more obvious trend than DDP group in HepG2. MiR-inhibitor-27a+DDP group revealed stronger expression in PI3K protein and weaker level of C-caspase-3, compared with DDP group in PLC. Silencing of miR-27a-3p attenuated the cisplatin effect. (C) The PI3K/Akt pathway inhibitors LY49002 was used, a significant suppression of PI3K/Akt signaling and an increased expression of C-caspase-3 was observed. When miR-27a-3p was knocked down, the above trend was attenuated in miR-inhibitor-27a group, compared with miR-inhibitor-Con group. β-actin was used as a loading control. All of the experiments were performed in triplicate. *P<0.05.